Conditions

Outcome Measures

Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM)
Change from baseline to 24-week endpoint in aLBM, as measured by dual energy x-ray absorptiometry (DEXA), is presented. Least squares (LS) means were calculated using a mixed model repeated measures (MMRM) with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline aLBM as covariate.
Baseline to 24 weeks

EXPERIMENTAL

Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.

Biological: LY2495655

PLACEBO COMPARATOR

Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.

Drug: Placebo

LY2495655BIOLOGICAL

Administered SC

LY2495655

Administered SC

Placebo

Age75 Years+

Sexall

Healthy VolunteersNo

Age GroupsOlder Adult (65+)

Sustained at least 1 fall within 1 calendar year before study screening.
Requires ≥12 seconds to perform a repeated chair stands test or is unable to complete this test at screening.
Hand grip strength is ≤37 kilograms (kg) for men (81.4 pounds) or ≤21 kg for women (46.2 pounds) at screening.
Can stand up from a chair and walk ≥10 meters without human assistance (gait aids such as cane\[s\], crutches, or walkers are acceptable) at screening.
Able to climb at least 1 step on a staircase without human assistance according to the participant at screening (using handrails is allowed).
Have screening clinical laboratory test results within normal reference range for the population, or have results with acceptable deviations that are judged to be not clinically significant by the investigator.

Major lower limb pain or neurologic impairment or vestibular vertigo or visual impairment that could severely confound measures of physical performance.
Recent lower limb fracture and/or major lower limb surgery.
Planned major surgical procedure within 6 months following study drug dosing.
Have had a lower extremity amputation of the foot, leg, and/or thigh.
Have a body mass index (BMI) ≥35 kilogram per meter squared (kg/m2).
Severe vitamin D deficiency.
Underlying muscle disease other than age-associated muscle waste or disuse atrophy.
Current use or previous use of any drugs known to influence muscle mass or performance.
Have had a recent neurologic injury (\<6 months before study drug dosing), such as stroke or spinal cord injury.
History of a malignant neoplasm in the 18 months before first study drug dosing.
Have a history or presence of unstable cardiovascular or pulmonary comorbidities.
Have a positive fecal occult blood (FOB) test at screening, or the participant cannot provide a stool sample for FOB testing before first study drug dosing.
Have either severe ongoing liver disease or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2 times upper limit of normal (ULN), alkaline phosphatase (ALP) \>1.5 times ULN, or total bilirubin \>1.5 times ULN at screening.
Have an estimated creatinine clearance \<20 milliliters per minute (mL/minute).
Have a history of severe allergic reaction to a monoclonal antibody.
+7 more criteria

Contact the study team to confirm eligibility.